Abstract
Direct-acting antiviral drugs (DAAs) were recently approved for treating hepatitis C virus-related chronic hepatitis. As advanced chronic liver disease may predispose patients to thrombotic events, it is still uncertain whether DAAs may influence the actual risk of major arterial and venous thrombotic events. We performed a systematic review to assess the incidence of major vascular events in patients receiving DAAs for HCV chronic hepatitis during phase-III randomized controlled trials (RCTs). Two reviewers identified studies through Pubmed database until October 2015. Reporting and incidence of any vascular events were compared with reporting and incidence of major bleeding, anemia (a prespecified safety outcome) and headache (a common non-prespecified safety outcome). 33 RCTs, encompassing 14,764 patients, were included. Only 13 (39%) and 4 (12%) RCTs provide data on any arterial or venous events, respectively. Occurrence of anemia and headache is reported in all studies. Crude unweighted rate of major arterial events is 0.16% (95% CI 0.10–0.24) of the total included population and 0.47% in those 13 RCTs reporting data. Crude unweighted rate of major venous events is 0.03% of the total included population (95% CI 0.01–0.08) and 0.22% in those four RCTs reporting data. Crude unweighted rate of major bleeding is 0.07% (95% CI 0.03–0.1). Incidence of thrombotic events in HCV patients receiving DAAs may be low, but an incorrect estimation cannot be excluded.
Similar content being viewed by others
References
Galli L, Gerdes VE, Guasti L, Squizzato A (2014) Thrombosis associated with viral hepatitis. J Clin Transl Hepatol 2(4):234–239
Tufano A, Di Capua M, Coppola A, Conca P, Cimino E, Cerbone AM et al (2012) The infectious burden in atherothrombosis. Semin Thromb Hemost 38(5):515–523
Deval J, Symons JA, Beigelman L (2014) Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus. Curr Opin Virol 9:1–7
Belousova V, Abd-Rabou AA, Mousa SA (2015) Recent advances and future directions in the management of hepatitis C infections. Pharmacol Ther 145:92–102
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, PRISMA-P Group et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2(349):g7647
D’Avolio A, Cusato J, De Nicolò A, Allegra S, Di Perri G (2016) Pharmacogenetics of ribavirin-induced anemia in HCV patients. Pharmacogenomics 17(8):925–941
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Cochrane Bias Methods Group, Cochrane Statistical Methods Group et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 18(343):d5928
Loke YK, Price D, Herxheimer A (2011) Chapter 14: Adverse effects. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. http://www.handbook.cochrane.org
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, ADVANCE Study Team et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364(25):2405–2416
Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, ALLY-2 Investigators et al (2015) Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373(8):714–725
Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, ASTRAL-1 Investigators et al (2015) Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373(27):2599–2607
Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, ASTRAL-2 Investigators, ASTRAL-3 Investigators et al (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373(27):2608–2617
Curry MP, O’Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, ASTRAL-4 Investigators et al (2015) Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373(27):2618–2628
Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C et al (2015) Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis 15(1):27–35
Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y et al (2015) Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163(1):1–13
Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H et al (2014) Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 61(2):219–227
Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H et al (2014) Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 49(5):941–953
Hayashi N, Seto C, Kato M, Komada Y, Goto S (2014) Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study. J Gastroenterol 49(1):138–147
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC et al (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368(20):1878–1887
Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, POSITRON Study, FUSION Study et al (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368(20):1867–1877
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, HALLMARK-DUAL Study Team et al (2014) All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 384(9954):1597–1605
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, HCV RESPOND-2 Investigators et al (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364(13):1207–1217
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, ILLUMINATE Study Team et al (2011) Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365(11):1014–1024
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, ION-1 Investigators et al (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370(20):1889–1898
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, ION-2 Investigators et al (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370(16):1483–1493
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, ION-3 Investigators et al (2014) Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370(20):1879–1888
Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H et al (2015) Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 15(6):645–653
Buti M, Agarwal K, Horsmans Y, Sievert W, Janczewska E, Zeuzem S et al (2014) Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. Gastroenterology. 146(3):744.e3–753.e3
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A et al (2014) ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 147(2):359.e1–365.e1
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, PEARL-III Study, PEARL-IV Study et al (2014) ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 370(21):1983–1992
Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P et al (2014) Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 146(7):1669.e3–1679.e3
Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV et al (2014) Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 384(9941):403–413
Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y et al (2014) Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384(9941):414–426
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, REALIZE Study Team et al (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364(25):2417–2428
Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M et al (2014) Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 370(17):1604–1614
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, SPRINT-2 Investigators et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195–1206
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K et al (2014) ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370(21):1973–1982
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, VALENCE Investigators et al (2014) Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 370(21):1993–2001
Bedossa P, Poynard T (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24(2):289–293
Ambrosino P, Lupoli R, Tarantino P, Di Minno A, Tarantino L, Di Minno MN (2015) Viral hepatitis and anti-phospholipid antibodies positivity: a systematic review and meta-analysis. Dig Liver Dis 47(6):478–487
Enger C, Forssen UM, Bennett D, Theodore D, Shantakumar S, McAfee A (2014) Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther 31(8):891–903
D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al (2008) General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117(6):743–753
Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41(1):3–14
Bosch J, Garcia-Pagan JC (2000) Complications of cirrhosis. 1. Portal hypertension. J Hepatol 32(1 Suppl):141–156
Gores GJ, Wiesner RH, Dickson ER, Zinsmeister AR, Jorgensen RA, Langworthy A (1989) Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 96(6):1552–1559
Ferro D, Angelico F, Caldwell SH, Violi F (2012) Bleeding and thrombosis in cirrhotic patients: what really matters? Dig Liver Dis 44(4):275–279
Stuijver DJ, Romualdi E, van Zaane B, Bax L, Büller HR, Gerdes VE et al (2015) Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. Intern Emerg Med 10(2):219–246
European Centre for Disease Prevention and Control (2016) Systematic review on hepatitis B and C prevalence in the EU/EEA. ECDC, Stockholm
Author information
Authors and Affiliations
Contributions
ETP performed data collection and analysis, manuscript writing and final approval. AS was involved in study design, data interpretation, manuscript writing and final approval. LG performed data collection. VEAG, LM and LG performed data interpretation, manuscript editing and final approval.
Corresponding author
Ethics declarations
Conflict of interest
None.
Statement of human and animal rights
This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent
None.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Tamborini Permunian, E., Gervaso, L., Gerdes, V. et al. Direct-acting antiviral drugs for chronic hepatitis C and risk of major vascular events: a systematic review. Intern Emerg Med 13, 775–790 (2018). https://doi.org/10.1007/s11739-018-1828-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-018-1828-8